Molecular and clinical diseasome of comorbidities in exacerbated COPD patients

European Respiratory Journal

Volumn 46, Issue 4, 2015, Pages 1001-1010

  Faner, Rosa ^a,b   Gutiérrez Sacristán, Alba ^c   Castro Acosta, Ady ^b,d   Grosdidier, Solène ^c   Gan, Wenqi ^e   Sánchez Mayor, Milagros ^c   Lopez Campos, Jose Luis ^b,f   Pozo Rodriguez, Francisco ^b,d   Sanz, Ferran ^c   Mannino, David ^e   Furlong, Laura I ^c   Agusti, Alvar ^a,b,g  

^a Fundació Privada Clinic per A la Recerca Biomèdica   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AIRFLOW; BLOOD VESSEL TONE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DISEASOME; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GENE INTERACTION; GENE ONTOLOGY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HOSPITALIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DISEASOME; PRIORITY JOURNAL; SMOKING; AGED; ALGORITHM; COMPLICATION; COMPUTER PROGRAM; INFORMATION PROCESSING; MEDICAL AUDIT; METABOLISM; MIDDLE AGED; PROTEIN ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

AGED; ALGORITHMS; CLINICAL AUDIT; COMORBIDITY; DATA COLLECTION; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROTEIN INTERACTION MAPPING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; SOFTWARE;

EID: 84943226586     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00763-2015     Document Type: Conference Paper

References (50)

1. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
2. Vestbo J, Hurd SS, Agusti AG, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187: 347-365.
3. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
4. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013; 1: 73-83.
5. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107: 1376-1384.
6. Diez D, Agusti A, Wheelock CE. Network analysis in the investigation of chronic respiratory diseases: from basics to application. Am J Respir Crit Care Med 2014; 190: 981-988.
7. Faner R, Cruz T, López-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775-788.
8. Fabbri LM, Beghe B, Agusti A. COPD and the solar system. Am J Respir Crit Care Med 2012; 186: 117-119.
9. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. toward the extinction of phenotypes? Ann Am Thorac Soc 2013; 10: Suppl., S125-S130.
10. Van Remoortel H, Hornikx M, Langer D, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 189: 30-38.
11. Divo MJ, Casanova C, Marin JM, et al. COPD comorbidities network. Eur Respir J 2015; 46: 640-650.
12. Faner R, Agusti A. Network analysis: a way forward to understand COPD multimorbidity. Eur Respir J 2015; 46: 591-592.
13. Grosdidier S, Ferrer A, Faner R, et al. Network medicine analysis of COPD multimorbidities. Respir Res 2014; 15: 111.
14. Pozo-Rodriguez F, Alvarez CJ, Castro-Acosta A, et al. Auditoria clinica de los pacientes hospitalizados por exacerbacion de EPOC en Espana (estudio AUDIPOC): metodo y organizacion del trabajo [Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC study): method and organisation]. Arch Bronconeumol 2010; 46: 349-357.
15. Pozo-Rodriguez F, López-Campos JL, Alvarez-Martínez CJ, et al. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC Study. PLoS ONE 2012; 7: e42156.
16. Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, et al. European COPD Audit: design, organisation of work and methodology. Eur Respir J 2013; 41: 270-276.
17. Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, et al. Variability of hospital resources for acute care of COPD patients: the European COPD Audit. Eur Respir J 2014; 43: 754-762.
18. Hidalgo CA, Blumm N, Barabasi AL, et al. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol 2009; 5: e1000353.
19. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
20. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
21. Bauer-Mehren A, Rautschka M, Sanz F, et al. DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks. Bioinformatics 2010; 26: 2924-2926.
22. Pinero J, Queralt-Rosinach N, Bravo A, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford) 2015; 2015: bav028.
23. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
24. Schaefer MH, Fontaine JF, Vinayagam A, et al. HIPPIE: Integrating protein interaction networks with experiment based quality scores. PLoS ONE 2012; 7: e31826.
25. Kaimal V, Bardes EE, Tabar SC, et al. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res 2010; 38: W96-W102.
26. Agusti A, Calverley P, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122-136.
27. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
28. Sichelstiel A, Yadava K, Trompette A, et al. Targeting IL-1beta and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation. PLoS ONE 2014; 9: e98440.
29. Mortaz E, Adcock IM, Shafei H, et al. Role of P2X7 receptors in release of IL-1beta: a possible mediator of pulmonary inflammation. Tanaffos 2012; 11: 6-11.
30. Oelsner EC, Pottinger TD, Burkart KM, et al. Adhesion molecules, endothelin-1 and lung function in seven population-based cohorts. Biomarkers 2013; 18: 196-203.
31. Carratu P, Scoditti C, Maniscalco M, et al. Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulm Med 2008; 8: 20.
32. Spiropoulos K, Trakada G, Nikolaou E, et al. Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma. Respir Med 2003; 97: 983-989.
33. Wedzicha JA, Donaldson GC. Rapid FEV1 decline, early COPD, and angiotensin-converting enzymes? Chest 2014; 145: 671-672.
34. Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest 2014; 145: 695-703.
35. Agusti A, Barbera JA, Wouters EF, et al. Lungs, bone marrow and adipose tissue: a network approach to the pathobiology of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1396-1406.
36. Roca M, Verduri A, Corbetta L, et al. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 2013; 43: 510-521.
37. McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39: 1097-1103.
38. Maier D, Kalus W, Wolff M, et al. Knowledge management for systems biology a general and visually driven framework applied to translational medicine. BMC Syst Biol 2011; 5: 38.
39. Kohl P, Crampin EJ, Quinn TA, et al. Systems biology: an approach. Clin Pharmacol Ther 2010; 88: 25-33.
40. Lam TK, Spitz M, Schully SD, et al. "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev 2013; 22: 181-188.
41. Marshall JK. Myocardial infarction, peptic ulcer and acetylsalicylic acid: of good and evil. Can J Gastroenterol 2009; 23: 618.
42. Faner R, Rojas M, MacNee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 306-313.
43. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
44. Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int 2014; 2014: 420134.
45. Barabasi AL. Network medicine - from obesity to the "diseasome". N Engl J Med 2007; 357: 404-407.
46. Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011; 183: 1129-1137.
47. Agusti A. The path to personalized medicine in COPD. Thorax 2014; 69: 857-864.
48. Frei A, Muggensturm P, Putcha N, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. J Clin Epidemiol 2014; 67: 904-911.
49. Faner R, Gonzalez N, Cruz T, et al. Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect. PLoS ONE 2014; 9: e97491.
50. Agusti A, Anto JM, Auffray C, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Am J Respir Crit Care Med 2015; 191: 391-401.